In This Section

Program

Wednesday, September 29, 2021

Thursday, September 30, 2021

Wednesday, September 29

Opening Session
10-10:45 a.m.

Welcome from Cochairs

Welcome from Lead Supporters
Lustgarten Foundation 

Rising Star Keynote
Molecular subtypes and vulnerabilities in pancreatic cancer
Andrew J. Aguirre, Dana-Farber Cancer Institute, Boston, Massachusetts

Break
10:45-11 a.m.
Session 1: Immunotherapy Translation in Progress
Moderator: Robert H. Vonderheide, Penn Medicine Abramson Cancer Center, Philadelphia, Pennsylvania
11 a.m.-12:45 p.m.

Dendritic cell corner stone of tumor immunity in PDAC
David G. DeNardo, Washington University School of Medicine, St. Louis, Missouri

Ex vivo co-culture system with patient-derived organoids to assess CXCR4 inhibitor as an immune modulating agent for human pancreas adenocarcinoma*
Emily Alouani, Columbia University, New York, New York

A phase II pilot trial of nivolumab (N) + albumin bound paclitaxel (AP) + paricalcitol (P) + cisplatin (C) + gemcitabine (G) (NAPPCG) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC)*
Erkut H. Borazanci, HonorHealth/TGen, Scottsdale, Arizona

High quality neoantigens are immunoedited in long-term pancreatic cancer survivors*
Luis A. Rojas, Memorial Sloan Kettering Cancer Center, New York, New York

Inhibition of focal adhesion kinase (FAK) improves pancreatic ductal adenocarcinoma’s response to immunotherapy by targeting cancer stem cells (CSCs)*
Yezi Zhu, Livestrong Cancer Institute, Austin, Texas

Discussant: Reginald Hill, Ellison Institute for Transformative Medicine of USC, Los Angeles, California

Discussion

Break
12:45-1:15 p.m.
Career Breakout Rooms
1:15-2 p.m.

Transitioning from Academics to Industry

David J. Shields, Pfizer, New York, New York
Christina Twyman-Saint Victor, Bristol-Myers Squibb, Piscataway, New Jersey


Collaborating with Industry

Channing Der, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Jane Grogan, Graphite Bio, South San Francisco, California


Starting Your Lab

Yuliya Pylayeva-Gupta, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Christopher J. Halbrook, University of California Irvine, Irvine, California


Getting Tenure

Zobeida Cruz-Monserrate, The Ohio State University Wexner Medical Center, Columbus, Ohio
Rushika M. Perera, University of California San Francisco, San Francisco, California


Balancing Clinical and Research Life

Susan Tsai, Medical College of Wisconsin, Wauwatosa, Wisconsin
Jen Jen Yeh, University of North Carolina, Chapel Hill, North Carolina


Mentoring the Mentor

Lisa Coussens, OHSU Knight Cancer Center, Portland, Oregon
Howard C. Crawford, Henry Ford Pancreatic Cancer Center, Detroit, Michigan

Break
2-2:15 p.m.
Session 2: Big Data
Moderator: Jen Jen Yeh, University of North Carolina, Chapel Hill, North Carolina
2:15-4 p.m.

Session Keynote
Proteogenomic characterization of pancreatic ductal adenocarcinoma
Hui Zhang, Johns Hopkins University, Baltimore, Maryland

Chromatin dynamics in vivo define coordinate functions of inflammation and mutant Kras in pancreatic tumorigenesis*
Rohit Chandwani, Weill Cornell Medicine, New York, New York

Integrative genomic characterization of therapeutic targets for pancreatic cancer*
Jimmy A. Guo, Broad Institute of MIT and Harvard, Cambridge, Massachusetts

Lung-tropic, liver-averse, primary PDAC tumors are associated with greater peripheral T cell diversity and have a unique, subtype-independent, gene-expression signature that significantly correlates with longer survival*
Jason M. Link, Oregon Health & Science University, Portland, Oregon

Discussant: Eric A. Collisson, University of California San Francisco, San Francisco, California

Discussion

Thursday, September 30

Keynote Lecture
Moderator: Jen Jen Yeh, University of North Carolina, Chapel Hill, North Carolina

10-10:45 a.m.

Using an integrative molecular epidemiology approach to battle pancreatic cancer in the era of precision medicine: Hope is on the horizon
Jennifer B. Permuth, H. Lee Moffitt Cancer Center, Tampa, Florida

Break
10:45-11 a.m.
Session 3: Metabolism and Ras Signaling
Moderator: Andrew M. Lowy, University of California San Diego, La Jolla, California
11 a.m.-12:45 p.m.

Session Keynote
Metabolic stress in pancreatic cancer progression and therapy
Cosimo Commisso, Sanford Burnham Prebys Medical Discovery Institute, San Diego, California

Kdm6 demethylases are critical regulators of pancreatic cancer initiation, progression and subtype specification*
Laura Leonhardt, University of California San Francisco, San Francisco, California

Targeting the sterol regulatory element-binding protein pathway in pancreatic ductal adenocarcinoma*
Stephanie Myers, Johns Hopkins University, Baltimore, Maryland

Collateral amplification of the KRAS linked gene PTHLH governs pancreatic cancer growth and metastasis and reveals a new therapeutic vulnerability*
Jason R. Pitarresi, University of Pennsylvania, Philadelphia, Pennsylvania

Loss of compensatory feedback mechanism involving splicing factor SRSF1 accelerates KrasG12D-mediated pancreatic cancer initiation*
Ledong Wan, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York

Discussant: Donita Brady, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

Discussion

Break
12:45-1:15 p.m.
Session 4: Tumor Microenvironment
Moderator: Marina Pasca Di Magliano, University of Michigan Medical School, Ann Arbor, Michigan
1:15-3 p.m.

Session Keynote:
Rebalancing dysregulated tumor microenvironments in pancreatic cancer progression
Rosandra N. Kaplan, National Cancer Institute, Bethesda, Maryland

Targeting the Wnt-YAP crosstalk as a therapeutic approach to treat pancreatic cancer*
Bekesho Geleta, Children’s Cancer Institute Australia, Sydney, NSW, Australia

The splanchnic mesenchyme during fetal development is the major source of pancreatic cancer associated fibroblasts*
Lu Han, Medical University of South Carolina, Charleston, South Carolina

Hedgehog represses angiogenesis in PDAC through a paracrine cascade mediated by Wif1*
Marie C. Hasselluhn, Columbia University, New York, New York

Cancer-associated fibroblasts sustain critical dependency of pancreatic cancer cells on exogenous lipids*
Charline Ogier, Fox Chase Cancer Center, Philadelphia, Pennsylvania

Extrinsic KRAS signaling shapes the pancreatic microenvironment through fibroblast reprogramming*
Ashley Velez-Delgado, University of Michigan, Ann Arbor, Michigan

Discussant: Mara H. Sherman, OHSU Knight Cancer Center, Portland, Oregon

Discussion

Break
3-3:15 p.m.
Debate: The KPC Model Has Helped to Advance Pancreatic Cancer Therapy: Agree or Disagree?
Moderator: Anirban Maitra, UT MD Anderson Cancer Center, Houston, Texas
3:15-4 p.m.

Kenneth P. Olive, Herbert Irving Comprehensive Cancer Center, New York, New York
Phoebe Phillips, University of New South Wales, Sydney, Australia

Discussion

Closing Statements
4:15-4:20 p.m.

*Short talk selected from proffered abstracts